瑞替普酶与阿替普酶治疗急性缺血性卒中的安全性和有效性:一项2期随机对照试验
这项多中心、前瞻性、随机对照、开放标签、盲法终点2期试验在中国17个中心纳入180例发病4.5小时内的急性缺血性卒中患者,按1:1:1随机接受瑞替普酶12+12 mg、瑞替普酶18+18 mg或阿替普酶0.9 mg/kg静脉溶栓。主要安全终点36小时内症状性颅内出血在三组间无显著差异(P=0.53),14天主要疗效终点三组相近;作者认为瑞替普酶耐受性良好、疗效特征与阿替普酶相似,其疗效和合适剂量需前瞻性验证。
要点
- 36小时内症状性颅内出血:瑞替普酶12+12 mg组5.0%、18+18 mg组1.5%、阿替普酶组2.0%(P=0.53)。
- 14天主要疗效终点:瑞替普酶12+12 mg组75.0%、18+18 mg组72.7%、阿替普酶组78.0%。
- 作者认为瑞替普酶耐受性良好、疗效特征与阿替普酶相似,合适剂量需前瞻性验证。
核心结论
- 作者认为,在中国发病4.5小时内的急性缺血性卒中患者中,瑞替普酶耐受性良好,疗效特征与阿替普酶相似。
- 作者指出,瑞替普酶用于急性缺血性卒中患者的疗效和合适剂量需要前瞻性验证。
研究设计与样本
- 多中心、前瞻性、随机对照、开放标签、盲法终点的2期临床试验,在中国17个中心开展。
- 纳入年龄18至80岁、符合标准静脉溶栓条件的急性缺血性卒中患者,按1:1:1随机分配。
- 2019年8月至2021年5月共随机分配180例:瑞替普酶12+12 mg组61例、瑞替普酶18+18 mg组67例、阿替普酶组52例;4例未接受研究药物。
- 给药方案:静脉瑞替普酶12+12 mg、静脉瑞替普酶18+18 mg或静脉阿替普酶0.9 mg/kg。
主要发现
- 主要安全终点36小时内症状性颅内出血(SITS定义):瑞替普酶12+12 mg组60例中3例(5.0%)、瑞替普酶18+18 mg组66例中1例(1.5%)、阿替普酶组50例中1例(2.0%),P=0.53。
- 主要疗效终点(改良意向治疗人群,溶栓后14天美国国立卫生研究院卒中量表评分不超过1分或较基线下降至少4分):瑞替普酶12+12 mg组60例中45例(75.0%,比值比0.85[95%CI 0.35-2.06])、瑞替普酶18+18 mg组66例中48例(72.7%,比值比0.75[95%CI 0.32-1.78])、阿替普酶组50例中39例(78.0%)。
关键数值与推荐
- 症状性颅内出血采用SITS定义,评估时间窗为36小时内。
- 主要疗效终点定义为溶栓后14天美国国立卫生研究院卒中量表评分不超过1分或较基线下降至少4分。
- 试验注册号:NCT04028518。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出,瑞替普酶用于急性缺血性卒中患者的疗效和合适剂量需要前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reteplase is a more affordable new-generation thrombolytic with a prolonged half-life. We aimed to determine the safety dose range of reteplase for patients with acute ischemic stroke within 4.5 hours of onset. METHODS: This is a multicenter, prospective, randomized controlled, open-label, blinded-end point phase 2 clinical trial. Patients with acute ischemic stroke aged between 18 and 80 years who were eligible for standard intravenous thrombolysis were enrolled from 17 centers in China and randomly assigned (1:1:1) to receive intravenous reteplase 12+12 mg, intravenous reteplase 18+18 mg, or intravenous alteplase 0.9 mg/kg. The primary safety outcome was symptomatic intracranial hemorrhage (SITS definition) within 36 hours. The primary efficacy outcome was the proportion of patients with the National Institutes of Health Stroke Scale score of no more than 1 or a decrease of at least 4 points from the baseline at 14 days after thrombolysis. RESULTS: Between August 2019 and May 2021, 180 patients were randomly assigned to reteplase 12+12 mg (n=61), reteplase 18+18 mg (n=67), or alteplase (n=52). Four patients did not receive the study agent. Symptomatic intracranial hemorrhage occurred in 3 of 60 (5.0%) in the reteplase 12+12 mg group, 1 of 66 (1.5%) in the reteplase 18+18 mg group, and 1 of 50 (2.0%) in the alteplase group (P=0.53). The primary efficacy outcome in the modified intention-to-treat population occurred in 45 of 60 (75.0%) in the reteplase 12+12 mg group (odds ratio, 0.85 [95% CI, 0.35-2.06]), 48 of 66 (72.7%) in the reteplase 18+18 mg group (odds ratio, 0.75 [95% CI, 0.32-1.78]), and 39 of 50 (78.0%) in alteplase group. CONCLUSIONS: Reteplase was well tolerated in patients with acute ischemic stroke within 4.5 hours of onset in China with a similar efficacy profile to alteplase. The efficacy and appropriate dosage of reteplase for patients with acute ischemic stroke need prospective validation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04028518.
引用
- Li S, Wang X, Jin A, et al. Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial. Stroke. 2023. PMID: 38152962. doi:10.1161/STROKEAHA.123.045193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。